Highlights
- Market Cap
- $1.22M
- Enterprise Value
- $38.90M
- EPS (TTM)
- -$5.29
- Total Revenue (TTM)
- $254.00K
- Gross Profit (TTM)
- -$8.00K
- EBITDA (TTM)
- -$31.75M
- Year Range
- $0.16 - $20.60
- ROA (TTM)
- -143.24%
- ROE (TTM)
- 413.63%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Kala Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Kala Pharmaceuticals, Inc. (KALA) has returned -68.86% so far this year and -96.98% over the past 12 months.
Kala Pharmaceuticals, Inc.
- 1D
- 1.23%
- 1M
- -54.45%
- YTD
- -68.86%
- 6M
- -88.69%
- 1Y
- -96.98%
- 3Y*
- -77.43%
- 5Y*
- -78.25%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jul 20, 2017, KALA's average daily return is -0.09%, while the average monthly return is +0.71%. At this rate, your investment would double in approximately 8.2 years.
Historically, 35% of months were positive and 65% were negative. The best month was Dec 2022 with a return of +621.2%, while the worst month was Sep 2025 at -86.4%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, KALA closed higher 44% of trading days. The best single day was Dec 28, 2022 with a return of +218.4%, while the worst single day was Sep 29, 2025 at -89.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.66% | -28.30% | -54.45% | -68.86% | |||||||||
| 2025 | 32.56% | -24.67% | -17.32% | -30.72% | -6.30% | 27.96% | 42.23% | 65.73% | -86.36% | -49.02% | 23.86% | -42.46% | -91.99% |
| 2024 | -0.71% | 3.31% | 11.00% | -14.43% | -1.47% | 5.51% | -8.32% | -10.00% | -2.57% | 23.51% | -2.59% | 1.20% | -0.86% |
| 2023 | -54.55% | -41.58% | 48.57% | 4.78% | -9.32% | 2.03% | 3.02% | -10.71% | -33.68% | -22.47% | -12.32% | 15.70% | -81.65% |
| 2022 | -26.88% | -25.17% | 108.46% | -52.93% | -46.39% | -13.84% | 10.00% | -7.88% | -27.17% | -42.64% | -16.69% | 621.17% | -36.94% |
| 2021 | 9.59% | -0.27% | -9.04% | 14.69% | -26.91% | -6.19% | -34.91% | -2.03% | -22.49% | -33.59% | 9.20% | -36.32% | -82.15% |
Benchmark Metrics
Kala Pharmaceuticals, Inc. has an annualized alpha of -26.76%, beta of 0.74, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 21, 2017.
- This stock participated in 193.69% of S&P 500 Index downside but only -98.74% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -26.76%
- Beta
- 0.74
- R²
- 0.01
- Upside Capture
- -98.74%
- Downside Capture
- 193.69%
Return for Risk
Risk / Return Rank
KALA ranks 10 for risk / return — in the bottom 10% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Kala Pharmaceuticals, Inc. (KALA) and compare them to a chosen benchmark (S&P 500 Index).
| KALA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.60 | 0.90 | -1.50 |
Sortino ratioReturn per unit of downside risk | -1.04 | 1.39 | -2.42 |
Omega ratioGain probability vs. loss probability | 0.85 | 1.21 | -0.36 |
Calmar ratioReturn relative to maximum drawdown | -0.98 | 1.40 | -2.38 |
Martin ratioReturn relative to average drawdown | -1.37 | 6.61 | -7.98 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore KALA risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kala Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kala Pharmaceuticals, Inc. was 99.99%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Kala Pharmaceuticals, Inc. drawdown is 99.99%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.99% | Sep 15, 2017 | 2145 | Mar 30, 2026 | — | — | — |
| -6.48% | Jul 31, 2017 | 9 | Aug 10, 2017 | 2 | Aug 14, 2017 | 11 |
| -4.43% | Aug 17, 2017 | 2 | Aug 18, 2017 | 6 | Aug 28, 2017 | 8 |
| -2.27% | Jul 25, 2017 | 2 | Jul 26, 2017 | 1 | Jul 27, 2017 | 3 |
| -1.51% | Sep 7, 2017 | 2 | Sep 8, 2017 | 2 | Sep 12, 2017 | 4 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kala Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kala Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KALA relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, KALA has a P/S ratio of 4.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |